Pharmaco Economics Analysis of COVID-19 Vaccines in Ukraine
Tsekhmister Yaroslav Volodymyrovych, Stepanenko Viktor Ivanovich, Konovalova Tetiana, Tsekhmister Bogdan Yaroslavovych
Journal of Pharmaceutical Research International · pp. 140–147 · Published 18 Jun 2021
10.9734/jpri/2021/v33i32A31727Abstract
Aims: To evaluate pharmacoeconomics for the vaccination of COVID-19 vaccine and analyze the cost-effectiveness for the vaccine in Ukraine. Study design: we have analyzed using models for the economics of coronavirus vaccine. Place and duration of study: Sample: population of Ukraine, data used from the official website of Ministry of Health, Ukraine. April - May 2021 Methodology: We have used the transmission model to analyze the vaccine strategy. Data were collected from official sources. We structured an age group model for evaluating high transmitters. Four strategies were organized and analyzed for analyzing the cost-effective strategy vaccination for everyone, no vaccination, and vaccination for old age only, high transmitters’ vaccination. Results: we have analyzed country specific cost-effective strategy for Ukraine depends upon the pandemic and economics of the country. Vaccinating older people was found to be the economically effective for Ukraine. In these study influences of discount rate analysis on QALY in Ukraine was done. When we vaccinate, high transmitters’ ratio was found to be 8.8% higher than for the elderly. This analysis suggests that vaccinating first the elderly group would not be so cost-effective. While doubling the cost for the vaccine, if the vaccine is available early with the scenario of pre-existing immunity has shifted cost-effectiveness for high transmitters than for the elderly in Ukraine Conclusion: we conclude from our pharmacoeconomic research study that cost effective analysis depends on pandemic and vaccinating elderly would be effective economically.
Cited by 10
Ivan Klymenko, Serhii Lobanov, Tetiana Zaichykova · Salud, Ciencia y Tecnología · 2025
T. Untung, R. Pandey, P. Johansson · Vaccine: X · 2024
Neonila Korylchuk, Roman Riabushko, Iryna Haman · Journal of Biochemical Technology · 2023
Yaqun Fu, Jingyu Zhao, Xia Wei · Frontiers in Public Health · 2022
Yaqun Fu, Jingyu Zhao, Peien Han · Journal of Evidence-Based Medicine · 2023
Francesc López, Martí Català, Clara Prats · 2021
Oscar Espinosa, Laura Mora, Cristian Sanabria · Systematic Reviews · 2024
Francesc López, Martí Català, Clara Prats · 2021
Francesc López, Martí Català, Clara Prats · Vaccines · 2021
V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin · FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology · 2022
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
- The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
- Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage
Article metrics
Real usage data collected on this platform.
10
Page views
0
PDF downloads
0
Outbound clicks
10
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.